Welcome

Thomas S. Mir, MD, PhD back

Journals and Books (01.09.2011)

36.    Sheikzadeh S, Kade C, Keyser C, Mir TS, et al
        Analysis of Phenotype and Genotype Information for the diagnosis of Marfan Syndrome
         Clin Genet 2011 Aug 26 (Epub ahead of print)

35.    Sarikouch S, Koerperich H, Dubowy KO, Mir TS, et al
        Impact of Gender and Age on Cardiovascular Function Late after Repair of Tetralogy of Fallot - Percentiles based on Cardiac Magnetic Resonance
         Circulation Cardiovasc Im. 2011, accepted

34.    Ruffer A, Klopsch C, Münch F, Mir TS, et al
        Aortic arch repair: Let it beat
         Thorac Cardiovasc Surg. 2011 April 28. Epub ahead of print

33.    Ruffer A, Arndt F, Potapov S, Mir TS, et al
        Early stage 2 Palliation is crucial in patients with a right ventricle to pulmonary artery conduit
         Thorac Cardiovasc Surg. 2011;91(3):816-22

32.    Rybczynski M, Treede H, Sheikzadeh S, Mir TS, et al
        Predictors of Outcome of Mitral Valve Prolaps in Patients with the Marfan Syndrome
         Am J Cardiol 2011 Feb 1;107:268-274

31.    Manow ML, Paulsen N, Rybczynski M, Mir TS, et al
        Analysis of costs and profits of ambulatory care of Marfan patients after initiation of a novel German legal directive (116b SGB V)
         Med Klin. 2010 Aug;105(8):529-37

30.    Mir TS, Rybczynski M, Bernhardt A, et al
        Frequency and age-related course of mitral valve dysfunction in Marfan Syndrome
         Am J Cardiol 2010 Oct 1;106(7):1048-53

29.    Sheikzadeh S, Rybczynski M, Habermann C, Mir TS, et al
        Dural ectasia in individuals with Marfan-like features but extension of mutations in the genes FBN1, TGFBR1 and TGFB2
         Clin Genet 2010 Jun 1 (Epub ahead of print)

28.    von Kodolitsch Y, Rybczynski M, Bernhardt A, Mir TS, et al
        Marfan Syndrome and the evolving spectrum of heritable thoracic aortic disease: Do we need genetics for clinical decisions?
         VASA. 2010 Feb;39(1):17-32 REVIEW

27.    Mir TS, Arndt F, Samson P, et al
        A Novel Innominate Vein-to-Common Atrium Fenestration at Fontan Completion
         Ann Thor Surg. 2010 May;89(5):e38-40

26.    Rüffer A, Danch A, Gottschalk U, Mir T, et al
        The Norwood procedure - does the type of Shunt determine outcome?
         Thorac Cardiovasc Surg. 2009;57(9):270-5

25.    Mortensen K, Aydin MA, Rybczynski M, Mir T, et al
        Augmentation index relates to progression of aortic disease in adults with Marfan syndrome
         Am J Hypertens. 2009;22(9):971-9

24.    Nir A, Lindiger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS
        Normal values, range and upper limits of N-BNP in infants and children. Analysis of combined data from 4 studies
         Ped Card. 2009;30(1):3-8. Epub 2008 Jul. REVIEW

23.    Rybczynski M, Bernhardt AMJ, Rehder U, Mir TS, et al
        The Spectrum of Syndromes and Manifestations in Individuals Screened for Suspected Marfan Syndrome
         Am J Med Gen. 2008;15;146A(24):3157-66

22.    Albers S, Meibohm B, Mir TS, et al
        Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure
         Brit J Clin Pharm. 2007;65:4:511-22

21.    Mir TS
         Über die Anwendung des Brain Natriuretic Peptide (BNP) in der Diagnostik der chronischen Herzinsuffizienz bei Kindern und Jugendlichen
         Habilitationsschrift zur Erlangung der Venia Legendi (Universitätsklinikum Hamburg Eppendorf), 2006

20.    Mir TS, Flato M, Falkenberg J, et al
         Plasma concentration of N-terminal Brain Natriuretic peptide in healthy children, adolescents and young adults: Effect of age and gender
         Pediatr Cardiol. 2006 Jan-Feb;27(1):73-7

19.    Albers S, Mir TS , Haddad M, et al
         N-terminal pro Brain natriuretic peptide: evaluation of pediatric reference values including method comparison and inter-labartory variability
         Clin Chem Lab Med. 2006;44(1):80-5

18.    Laer S, Elshoff JP, Meibohm B, Mir TS, et al
         Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacodynamics in children with SVT
         J Am Coll Cardiol. 2005 Oct 4;46(7):1322-30

17.    Mir TS, Haun C, Läer S, et al
         Utility of N-BNP plasma concentrations in comparison to Lactate and Troponin in children following open-heart surgery
         Pediatr Cardiol; 2005;26:1-9

16.    Mir TS, Falkenberg J, Friedrich, et al
         Brain natriuretic peptide in pediatric patients with right ventricular overload due to congenital heart defects
         Cardiol Young. 2005 Aug;15(4):396-401

15.    Mir TS, Laux R, Hellwege HH, et al
         Plasma N-terminal pro-atrial-natriuretic peptide and plasma N-terminal-pro brain natriuretic peptide in healthy neonates: Marked and rapid
         increase after birth.
         Year Book of Neonatal and Perinatal Medicine, Mosby 2004 (3) PN 44         Book

14.    Mir TS, Läer S, Eiselt M, et al
         Effect of carvedilol on heart rate corrected QT-duration and QT dispersion in pediatric patients with congestive heart failure.
         Clin Drug Invest 2004;24 (1) 1-7

13.    Ganschow R, Richter A, Grabhorn E, Mir TS, et al
         C2 Blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kilograms.
         Pediatric Transplantation, 2004; 8: 185-188

12.    Mir TS, Stieh J
         Immunsuppression und Herztransplantation. In: Ganschow R. Immunsuppression in der pädiatrischen Transplantationsmedizin.
         Uni-Med Science, Bremen 1. Auflage; 42-51 (2004)             Book

11.    Mir TS, Laux R, Hellwege HH, et al
         Plasma N-terminal pro-atrial-natriuretic peptide and plasma N-terminal-pro brain natriuretic peptide in healthy neonates: Marked and rapid
         increase after birth.
         Pediatrics Oct;112, 896-99 (2003)

10.    Scholz H, Läer S, Behn F, Mir TS, et al
         Effects of the beta-adrenoceptor blocker carvedilol in children with myocardial failure
         Kluwer Academic Publishers, Boston, Chapter 8; 451-462 (2003)        Book

9.      Mir TS, Marohn S, Läer S, et al
         Plasma concentrations of N-terminal-pro brain natriuretic peptide in children from neonatal period to adulthood and in children with congestive
         heart failure.
         Pediatrics Dec;110(6), 1-6 (2002)

8.      Läer S, Mir TS, Behn F, et al
         Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters.
         Am Heart J, 143, 916-922 (2002)

7.      Läer S, Meibohm B, Mir TS, et al
         Termination of supraventricular tachycardia in an infant by adequate sotalol dosing:
         Evidence for clinically relevant age-dependent pharmacokinetics.
         Eur J Clin Pharmacol, 57, 181-182 (2001)

6.      Behn F, Läer S, Scholz H, Mir TS.
         HPLC quantification of carvedilol in small plasma samples from children.
         Chromatographia, 53, 641-644 (2001)

5.      Läer S, Wauer I, Behn F, Mir TS, et al
         Pharmacokinetics of sotalol in different age groups of children with tachycardia.
         J Pediatr Pharmacol Ther, 6, 50-59 (2001)

4.      Mir TS, Brockhoff C, Eiselt M , et al
         Messung der gesundheitsbezogenen Lebensqualität (LQ) von Erwachsenen mit angeborenen Herzerkrankungen mit dem SF-36 Health Survey
         J Kardiol 2000; 7 (12) 506 511 (2000)

3.     Mir TS, Eiselt M, Läer S, et al
        Chronische Herzinsuffzienz bei pädiatrischen Patienten Erste klinische Erfahrungen in der zusätzlichen Therapie mit Carvedilol.
        Pädiatrie & Pädologie 6, 24-31 (2000)

2.     Heinzer H, Mir TS, Huland E, et al
        Subjective and objective prospektive, long-term analysis of Quality of life during inhalted Interleukin-2 Immunotherapy
        J Clin Oncol Nov;17(11): 3612-3620 (1999)

1.     Huland E , Heinzer H, Mir TS, et al
        Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience
        Cancer J Sci Am Dec; 3 Suppl 1: S 98-105 (1997)

And more than 100 abstracts on national and international meetings

Awards

8 .       Member of the Science Committee of the "Deutsche Gesellschaft für Pädiatrische Kardiologie"
           General Meeting of the DGPK, 05.10.08, Neu-Ulm

7.        Award "Teacher of the Year" Unikinik Hamburg Eppendorf
           Ceremony 24.01.2008, Hamburg
           Students evaluation at the faculty of the University Clinics Hamburg Eppendorf

6.        Science Award of the "Deutschen Gesellschaft für Pädiatrische Kardiologie - DGPK 2007",
           Dotation 4000 Euro. (07.10.2007, Ulm)
           Anwendung des Brain Natriuretic Peptide in der Diagnostik der chronischen Herzinsuffizienz bei Kindern und Jugendlichen

5.         Best Poster during the congress of "Norddeutschen Gesellschaft für Kinderheilkunde und Jugendmedizin"
           ( 51. Jahrestagung vom 26.-28. April 2002 in Hamburg). Nt-pro-brain natriuretic peptide (N-BNP) zur Diagnostik
            Risikostratifizierung und Therapiesteuerung bei Kindern mit angeborenen und erworbenen Herzerkrankungen.

4.        Science Award of the"Kuratiorium des Bundesverbandes Herzkranke Kinder e.V. and the DGPK 2001",
           Dotation 10.000 DM. (09.10.2001, Bad Oeynhausen)
           Effektive und sichere Sotalol-Therapie von herzkranken Kindern mit supraventrikulären Tachykardien. TS Mir und S Läer

3.        Highlight of the XXII Congress of the European Society of Cardiology (ESC) in Amsterdam 2000:
           August 26 to 30, 2000; In Congenital Heart Disease: Imaging and Other Tests of Function. McGuirre, Am Heart J. 2001 Jan;141(1):164-172.
           Treatment of congestive heart failure with carvedilol in pediatric patients. Mir TS

2.       Science Award des Kuratiorium der Dr. Martini-Stiftung von 1880
          Dotation 21.000 DM (11.02.2000, Hamburg)
          Beta-Receptortherapy on young children with congestive heart failure: A study with carvedilol. Mir TS und S Läer

1. Best Poster 1999 during the congress of the"Deutsche Gesellschaft für pädiatrische Kardiologie" ( 2 - 5. 10. 1999) in
Wuppertal (S. Läer, TS Mir). Differences in carvedilol pharmakokinetics between children and adults

Projekts

Secretary of the 40. meeting of the DGPK (04.-07.10.08 Neu-Ulm, Germany)

Kompetenznetzwerk Angeborene Herzfehler / gefördert durch das BMBF
Center of competence for Congenital Heart Disease / Foundation of German Ministry of Health

-Projekt Messung der Lebensqualität im Kompetenznetzwerk
Quality of Life in children with congenital heart disease

-Projekt medikamentöse Behandlung der rechtsventrikulären Herzinsuffizienz
Medical treatment of right ventricular heart failure

-Projekt "Prävalenz Angeborene Herzfehler" (PAN)
Prevalence of congenital heart disease (PAN)

Working Groups

AG Pädiatrische Herz und Lungentransplantation. Erstellung eines nationalen
Standards zur perioperativen Diagnostik und Therapie. Aufbau eines Registers.

Working Group on Pediatric Heart and Lungtransplantation.

Heart Failure Association of the European Society of Cardiology (ESC)

Membership

German Society of Pediatric Cardiology (DGPK)

Member of the Science Committee of the DGPK

German Society of Pediatrics (DGKJ)

Association for European Pediatric Cardiology (AEPC)

Others

Reviewer for PEDIATRICS, PED CARD, CARDIOLOGY IN THE YOUNG, ACTA PAEDIATRICA, EUR J PED, ARCH DIS CHILD, EPILEPSIA, CLIN CHEM, CLIN RES CARD and many others